Three decades at the bench, the boardroom, and the regulatory table.

AlaBioPharma was founded on a simple conviction: the most expensive decisions in drug development are the ones made too quickly, with too little science behind them. Our role is to slow those decisions down just enough to get them right.

Dr. Hudzik has spent more than thirty years inside the bio-pharmaceutical industry, advancing small molecule and cell therapies through preclinical and clinical testing. His record includes over one hundred peer-reviewed scientific publications and conference presentations, with focus on the central nervous system, abuse liability, neuropsychiatry, and translational medicine.

He has served as a grant reviewer for the National Institutes of Health and an advisor to the World Antidoping Agency. He brings that perspective — academic, regulatory, and industrial — to every engagement.